Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity

Mostafa Abdelsalam 1*, Ekramy Elmorsy 2, Hassan Abdelwahab 1, Osman Algoheyay 1, Mahmoud Naguib 1, Ahmed Abd El Wahab 1, Ahmed Elddeeb 1, Ehab Elторaby 3, Adel Abdelsalam 3, Alaa Sabry 1, Mohamed El-Metwally 3, Mohamed Akl 4, Nahla Anber 5, Maysaa El Sayed Zaki 6, Fahad Almutairi 7 and Tamer Mansour 6,8

Abstract

Background: Nephrotoxicity is a major hazard complicating the use of platinum based drugs (PBD), which can hinder using higher doses protocols to maximize the therapeutic gain. Shortage of serum creatinine level as an accurate biomarker for acute kidney injuries (AKI) necessitates searching for novel biomarkers with better sensitivity and specificity in patients on PBD.

Methods: In a prospective cohort design, 132 patients receiving PBD were selected for the study. AKI was diagnosed by continuous follow up of serum creatinine level according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2012. Serum creatinine and urinary biomarkers (KIM-1, NGAL and cystatin C) was measured in the day of treatment and for 3 days after PBD cycle.

Results: AKI occurred in 35 patients (26.52% of patients). KIM-1, Cystatin C, and NGAL showed significant increase in samples collected in the day of AKI in comparison to their corresponding basal levels \((P<0.0001)\). In addition, significant increase in urinary levels of the biomarkers in samples collected 1 day before AKI in comparison to their basal levels \((P<0.0001, P<0.0001, \text{and } P=0.013 \text{ for KIM-1, NGAL and Cystatin C respectively})\). Furthermore KIM-1 data showed a significant increase 2 days before serum creatinine rise in comparison to the corresponding KIM-1 levels in patients who developed AKI \((P=0.001)\).

Conclusions: Urinary KIM-1, Cystatin C and NGAL can predict PBD induced AKI in earlier stages than serum createnine. KIM-1 is the most sensitive biomarker for early detection of AKI in patients receiving PBD.

Keywords: Platinum based drugs, Cisplatin, Oxaplatin, Urinary biomarkers, Nephrotoxicity

Background

Kidney is a major target for the toxicities of different chemicals and drugs. Chemicals induced nephrotoxicity was reported in about 8–60% of hospital-acquired acute kidney injuries (AKI) cases [1]. However it is not clear in these studies whether AKI was the primary reason for hospitalization or it was hospital acquired. Studies showed a marked increase in AKI incidence from 1980 to 2005 from 18 cases per 100,000 populations in 1980 to 365 cases per 100,000 populations [3, 4]. However, this increase in uncertain to be due to actual increase in number of cases, more ageing or increased awareness.

Diagnosis and classifications of AKI mainly depends on serum creatinine which can lead to wrong interpretation in patients whose creatinine kinetics and volume of distribution are variable or extreme [2]. On the other hand, minimal increases in serum creatinine were associated with considerable high rates of mortality which decreases the value of serum creatinine as a diagnostic and follow up tool in cases with AKI [5]. Several biomarkers were studied to detect earlier stage of renal dysfunction before it disrupts renal filtration capacity. These biomarkers are able to give accurate screening of the renal functions compared to routine renal investigations. Promising renal
b biomarkers include N-acetyl-β-glucosaminidase (NAG), β2-microglobulin (β2M), Cystatin-C (Cys-C), Kidney injury molecule-1 (KIM-1), Clusterin and Human neutrophil gelatinase-associated lipocalin (NGAL) [6, 7]. Strong predictive effect of urinary KIM-1 was documented previously in cases of acute tubular necrosis [8], scrub typhus [9]. In addition, KIM-1 was reported to predict proximal tubular injury after renal transplantation [10]. Regarding specificity and sensitivity of KIM-1 in cases of AKI meta-analysis study showed The estimated sensitivity of urinary KIM-1 for the diagnosis of AKI was 74.0% (95% CI, 61.0–84.0%), and specificity was 86.0% (95% CI, 74.0–93.0%) in 2979 cases from 11 published studies [11]. Urinary Cys-C had been reported to increase in tubular dysfunction [12]. Moreover, elevated urinary Cys-c was reported as bad prognostic sign in cases with non-oliguric AKI [13]. Regarding NGAL, animal models showed that it is one of the most up-regulated genes in cases of AKI [14]. Subsequent human studies confirmed its significance as a biomarker for AKI [15, 16].

Platinum based drugs (PBD), which includes Cisplatin, Oxaplatin and Carboplatin, is widely used in treatment of different malignant diseases [17]. Kidney injuries were reported in about 25–34% of patients receiving a single dose of Cisplatin [18] with increased incidence and severity of accumulative nephrotoxicity with the subsequent cycles [19, 20]. Kidney injury is considered the most dangerous side effect and can reduce the doses of Cisplatin in its designed protocols, limiting its clinical use and efficacy [21]. Some cases were reported with Oxaliplatin based chemotherapy as well [22–24].

Carboplatin is used as a safer PBD with less reported nephrotoxicity; however its myeloablative doses of 800 mg/m² were shown to be nephrotoxic [25]. Also, acute interstitial nephritis was reported in 2 cases receiving Carboplatin [26]. In addition, Carboplatin induced hematuria and AKI in an old patient on Carboplatin for ovarian carcinoma was reported [27]. Furthermore, grades 1 and 2 nephrotoxicity were reported in 4–5% of cases receiving Carboplatin [28].

The aim of the current work is to assess the levels of urinary KIM-1, uNGAL and Cys-C as biomarkers for early detection of acute kidney injury in patients receiving PBD in a prospective unicenter study in Mansoura university hospitals, Egypt.

Methods

Ethical issues

The current study was approved by the ethical committee of Mansoura Faculty Medicine. A free voluntary informed consent was taken from all participants. Confidentiality and privacy were considered regarding participants’ personal, clinical and laboratory data.

Patient selection

All patients enrolled in the study had received PBD for curative treatment, within the period from April 2015 to April 2016, in department of Clinical Oncology and Nuclear Medicine in Mansoura University Hospital, Dakahlya Governorate, Egypt. Patients with normal kidneys seen by pelvi-abdominal ultrasound and normal kidney functions approved by laboratory investigations were included (serum creatinine less than1.1 mg/dl, estimated glomerular filtration rates higher than 90 ml/min by The Modification of Diet in Renal Disease MDRD equation). Patients with renal dysfunction at the beginning of therapy and those who received platinum based drugs as a palliative treatment were excluded from the study. Patients with active infection, heart failure or diabetes mellitus, thyroid disorders or suprarenal diseases were also excluded. Any patient with known history of renal disease, operations or intake of a nephrotoxic drug or contrast enhanced imaging within the previous 30 days were not enrolled in the study. In addition patient with bad general condition due to anemia, dehydration, elevated liver enzymes or cerebral metastasis were also excluded. After application of exclusion criteria, 132 patients (74 males and 58 females) were selected to continue through the study. All participants were properly hydrated following hydration protocol shown in Table 1.

Study design

From all participants, 5 ml venous blood samples were withdrawn in the morning of PBD (just before administration of PBD) and for the subsequent 3 days of each

Table 1 Hydration protocol used for cases enrolled in the study during platinum based drugs (PBD)

| Before PBD: |
| --- |
| i. 1000 mL Sodium Chloride 0.9% |
| ii. 500 ml sodium chloride with 20mmolKCL |
| iii. 500 ml sodium chloride with 10 mmol MgSO4 |

| During administration of PBD: PBD is given in 1000 mL Sodium Chloride 0.9% infused over 2 h |
| --- |
| After PBD: 1000 mL Sodium Chloride 0.9% with 20 mmol KCL and 10 mmol MgSO4 IV |

| Monitoring during chemotherapy: |
| --- |
| i. Monitor urine output at regular intervals throughout chemotherapy |
| ii. At the end of IV fluids, weigh the patient and review fluid input and output |
| iii. Re-weigh the patient – if they have gained > 2 kg, they should be prescribed furosemide 20 mg orally and urine output monitored for a further 30 min. |

| Pre-discharge: |
| --- |
| i. Ensure the patient is able to maintain good oral fluid intake |
| ii. Patient should be advised to drink a lot of fluids |
| iii. Advise patient to contact the hospital if unable to drink due to vomiting |

| After PBD: 1000 mL Sodium Chloride 0.9% with 20 mmol KCL and 10 mmol MgSO4 IV |

| Monitoring during chemotherapy: |
| --- |
| i. Monitor urine output at regular intervals throughout chemotherapy |
| ii. At the end of IV fluids, weigh the patient and review fluid input and output |
| iii. Re-weigh the patient – if they have gained > 2 kg, they should be prescribed furosemide 20 mg orally and urine output monitored for a further 30 min. |

| Pre-discharge: |
| --- |
| i. Ensure the patient is able to maintain good oral fluid intake |
| ii. Patient should be advised to drink a lot of fluids |
| iii. Advise patient to contact the hospital if unable to drink due to vomiting |
treatment cycle. Blood samples were allowed to clot for 15 min then centrifuged for 10 min at 5000 g to obtain the serum. Creatinine was measured by using modified rate Jaffe method, using commercially available kits supplied for Human samples (Germany) [29].

For urinary markers assay, 10 ml of mid-flow urinary samples were collected in disposable urine cups without preservatives at the same time points of blood sampling. Urine samples were centrifuged at 1000 g for 5 min and supernatants were stored at −20 °C. Urinary KIM-1, NGAL and Cys-C levels were measured using (ELISA kit supplied by Sunred Biological Technology, china) following the manufacturer protocol. Each sample was studied as triplicate and the average of the three readings was considered as the actual value of the urinary biomarkers. Samples with odds readings were repeated. All assays were done by the same technician using the same equipment. For biomarkers data validation inter-assay and inter-assay variability was estimated following [30].

**Statistical analysis**

Data were verified. All statistical procedures were performed using PRISM 5 (GraphPad Software Inc., San Diego, CA). Repeated measures two-way ANOVA was used for statistical analysis of changes in the levels of the studied biomarkers over the course of the study. Dunnett’s multiple comparisons test was used to compare

---

**Table 2** Demographic characters, types of cancers, platinum based chemo therapeutic courses and the basal laboratory data of the studied population

| Parameters                  | AKI (+) 35 (100%) | AKI (-) 97(100%) | p-value | Totals 132 (100%) |
|-----------------------------|-------------------|------------------|---------|-------------------|
| Demographic data            |                   |                  |         |                   |
| a. Age (Mean ± SD)          | 50.57 ± 13.33      | 49.25 ± 13.29    | 0.615   |                   |
| 1. <30Y                     | 4 (11.8%)          | 7 (7.1%)         |         | 11(8.3%)          |
| 2. 30–50                    | 10 (28.6%)         | 38 (39.1%)       | 0.68    | 48 (36.4%)        |
| 3. > 50                     | 21 (60.1%)         | 52 (53.6%)       |         | 73 (55.3%)        |
| b. Gender                   |                   |                  |         |                   |
| 1. Males                    | 17 (48.6%)         | 57 (58.8%)       | 0.298   | 74 (56%)          |
| 2. Females                  | 18 (51.4%)         | 40 (41.2%)       |         | 58 (44%)          |
| c. BMI                      | 23.3 ± 4.1         | 24.3 ± 3.4       | 0.161   | 23.5 ± 4.8        |
| Type of cancer              |                   |                  |         |                   |
| a. Gastrointestinal         | 19 (54.3%)         | 61 (62.9%)       | 0.615   | 80 (60.6%)        |
| b. Respiratory              | 6 (17.2)           | 21 (21.7%)       |         | 27 (20.5%)        |
| c. Reproductive             | 2 (5.7%)           | 6 (6.3%)         | 0.5     | 8 (6%)            |
| d. Neuroendocrine           | 2 (5.7%)           | 2 (2.1%)         |         | 4 (3%)            |
| e. Osteosarcoma             | 2 (5.7%)           | 2 (2.1%)         |         | 4 (3%)            |
| f. Others                   | 4 (11.4%)          | 5 (5.25%)        | 0.161   | 9 (6.8%)          |
| Received PBD agent:         |                   |                  |         |                   |
| a. Cisplatin (50 mg/m2)     | 22 (62.9%)         | 49 (50.5%)       | 0.45    | 71 (53.8%)        |
| b. Oxaliplatin (85 mg/m2)   | 12 (34.3%)         | 41 (42.3%)       |         | 53 (40.2%)        |
| c. Carboplatin*             | 1 (2.9%)           | 4 (4.1%)         |         | 5 (3.8%)          |
| d. Cispaltin (50 mg/m2) + Carboplatin | 0 | 3 (3.1) | 3 (2.3%) |
| Basal line laboratory data before PBD: | |                   |         |                   |
| a. Ser. Cr. (mg/dl)         | 0.73 ± 0.2         | 0.74 ± 0.3       | 0.85    | 0.73 ± 0.4        |
| b. BUN (mmol/L)             | 4.5 ± 1.7          | 4.6 ± 1.5        | 0.74    | 4.5 ± 2           |
| c. eGFR (ml/min)            | 102 ± 4            | 103 ± 5.2        | 0.3     | 102 ± 5.7         |
| d. Sodium (mmol/L)          | 137.3 ± 5.1        | 136.6 ± 4.6      | 0.45    | 136.9 ± 5.8       |
| e. Potassium (mmol/L)       | 3.6 ± 0.7          | 3.7 ± 0.6        | 0.42    | 3.6 ± 0.9         |
| f. Calcium (mg/dl)          | 9.66 ± 1.05        | 9.50 ± 0.50      | 0.412   | 9.5 ± 1.1         |

KIM-1

(0 day) 1.04 ± 0.2 (0.84–1.24) 1.2 ± 0.21 (0.99-1.41) 0.39

BUN: Blood urea Nitrogen, Estimated glomerular filtration. * Carboplatin dose was calculated by Calvert formula.
baseline values with individual data groups. ROC curve statistics were used to estimate specificity and sensitivity of the markers. Independent t-test was used to compare 2 unpaired groups of data, while Chi-square was used to compare nominal data. Statistic results were considered statistically significant when \( p \) values were less than 0.05.

**Results**

In this study, 35 (26.5%) cases had developed AKI with increased serum creatinine during the course of the study according to KDIGO criteria (2012) [31]. There was no significant difference between patient groups, with or without AKI, regarding demographic characters, baseline laboratory data or types of cancers (Table 2). Number of patients who received Cisplatin, Oxaliplatin and Carboplatin are shown in Table 1. About 32% and 22% of patients receiving Cisplatin and Oxaliplatin respectively developed AKI, while only one patient developed AKI among six patients who received Carboplatin. Highest number of cases developed AKI in the 3rd cycle [11 patients (31.4%)] followed by the 2nd cycle [9 patients (25.7%)]. AKI was also diagnosed in 6 participants (17%) in the 1st cycle and in 4 cases after the 4th and 5th cycles.

For validation of the urinary biomarkers data inert-assay and intra-assay variability of the studied biomarkers were estimated (Table 3). All the studied urinary markers (urinary KIM-1, Cys-C, and NGAL) showed significant increase in AKI group in the day of diagnosis and one day before serum creatinine increase (Tables 4 and 5). Only KIM-1 showed significant increase 2 days before serum creatinine based AKI diagnosis \( P = 0.001 \). KIM-1 showed the highest percentage of increase all over the course of AKI in comparison to the other studied urinary biomarkers (Table 6). Interestingly, although cisplatin was reported to be the most nephrotoxic PBD agent, there was no significant difference between the studied AKI cases regarding the level of increase of each biomarker among the patients groups following different protocols using the different PBD agents.

The basal levels of KIM-1, Cys-C, and NGAL (before the chemotherapy) were compared with their levels after treatment in the AKI group. ROC curve shows levels of cut off with the highest sensitivity and 100% specificity (Table 7 and Fig. 1).

**Discussion**

PBD is an efficient chemotherapy used in different malignancies; however it carries high risk of AKI even in cases with good hydration. In the current study, 3 well-known urinary biomarkers (KIM-1, Cys-C, NGAL) of kidney injury were evaluated for early diagnosis of PBD-induced AKI in comparison to the routinely used serum creatinine. In the last years, several studies tried to use KIM-1, Cys-C and NGAL as sensitive biomarkers

---

**Table 3** Inter-assays and inter-assay variability of the studied urinary biomarkers ELISA assays

| Urinary biomarker | Inter-assay variability | Intra-assay variability |
|-------------------|------------------------|------------------------|
| KIM-1             | High (10 ng/ml) = 8.2% | 4.53%                  |
|                   | Low (0.1 ng/ml) = 11.46%|                       |
| NGAL              | High (1000 ng/ml) = 9.1%| 5.45%                  |
|                   | Low (10 ng/ml) = 5.5%  |                        |
| Cys-C             | High (100 ng/ml) = 5.97%| 6.76%                  |
|                   | Low (10 ng/ml) = 7%    |                        |

**Table 4** Urinary biomarkers data of the studied population represented as means ± standard deviation (lower limit- upper limit)

| Biomarkers (ng/ml) | AKI (+) 35 cases | AKI (−) 97 cases | \( p \)-value |
|--------------------|------------------|-----------------|----------------|
| 1. KIM-1           |                  |                 |                |
| Day 0              | 1.04 ± 0.2 (0.84–1.24) | 1.2 ± 0.21 (0.99–1.41) | 0.39          |
| Day 1              | 1.5 ± 0.2 (1.3–1.7)   | 1.3 ± 0.2 (1.1–1.5)   | 0.62          |
| Day 2              | 2.1 ± 0.19 (1.91–2.29) | 1.2 ± 0.27 (0.93–1.47) | 0.0092**      |
| Day 3              | 2.25 ± 0.18 (2.07–2.43) | 1.4 ± 0.2 (1.2–1.6) | 0.0054**      |
| 2. NGAL            |                  |                 |                |
| Day 0              | 416 ± 46.7 (369.3–462.7) | 413 ± 49.6 (363.4–462.6) | 0.92          |
| Day 1              | 426.3 ± 52.34 (373.69–478.64) | 419.2 ± 58.4 (360.8–477.6) | 0.92          |
| Day 2              | 573.2 ± 39.24 (533.69–612.44) | 422.8 ± 38.3 (384.5–461.1) | 0.0032**      |
| Day 3              | 611.6 ± 46.35 (565.25–657.95) | 420.8 ± 42.3 (478.5–463.1) | 0.0088**      |
| 3. Cys-C           |                  |                 |                |
| Day 0              | 14.5 ± 1.49 (13.01–15.99) | 12.48 ± 1.42 (11.06–13.9) | 0.22          |
| Day 1              | 15.6 ± 1.7 (13.9–17.3) | 12.9 ± 1.1 (11.8–14) | 0.12          |
| Day 2              | 18.6 ± 1.9 (16.7–20.5) | 13.26 ± 0.68 (12.58–13.94) | 0.013*        |
| Day 3              | 22.1 ± 2.28 (19.82–24.38) | 13.44 ± 0.53 (12.9–13.97) | 0.003**       |

Day 0 means the day of PBD intake. Day 1, day2 and day3 means one, two and three days after PBD intake
* means \( p < .05 \), ** means \( p < .01 \)
for early detection of AKI among patients receiving PBD. To the best of our knowledge, this study is the first study which tried to combine those three urinary biomarkers in a one comparative study and with the new design for AKI detection.

In the current study of 132 patients who received PBD, 26.5% developed AKI. In recent studies, the incidence of AKI among patients on Cisplatin based chemotherapy was about 34% [32, 33]. This difference may be due to the higher Cisplatin doses received in these studies (≥ 60 mg/m²). The current data revealed 22% as incidence of AKI among patient received Oxaliplatin, which is relatively higher than expected. This higher incidence may be related to the followed protocol dose, the general condition of the patient and their compliance with the followed hydration protocols. Some of our patients received Carboplatin and Oxaplatin as an alternative chemotherapeutic drugs in their protocol of therapy with less nephrotoxic effect.

In the current study basal levels of urinary biomarkers were used and compared with the subsequent value in the same individual using repeated measures statistics as it will be more accurate than the comparisons of means as the basal levels of these biomarkers vary among the healthy population.

AKI was diagnosed in the 3rd day of PBD administration using serum creatinine based on KDIGO 2012 criteria [31]. The current data revealed that all the studied markers showed significant increase in samples collected one day before AKI diagnosis ($P = 0.004$, $P = 0.009$, and $P = 0.01$ for KIM-1, Cys-C and NGAL respectively). Even more, KIM-1 data showed significant increase 2 days

### Table 5

| Biomarkers (ng/ml) | AKI (+) 35 cases | AKI (-) 97 cases |
|-------------------|------------------|-----------------|
|                   | Dunnett’s multiple comparisons | Two way ANOVA $p$-value | Two way ANOVA $p$-value |
| 1. KIM-1          |                   |                 |                      |
| Day 0 versus day 1| < 0.048*          | 0.58            | 0.94                |
| Day 0 versus day 2| < 0.0026**        | < 0.0002***     | 1                   |
| Day 0 versus day 3| < 0.0015**        | 0.29            |                     |
| Day 1 versus day 2| 0.019*            | 0.63            |                     |
| Day 2 versus day 3| 0.37             | 0.36            |                     |
| 2. NGAL           |                   |                 |                      |
| Day 0 versus day 1| 0.81             | 0.89            |                     |
| Day 0 versus day 2| 0.011*           | 0.0015**        | 0.81                |
| Day 0 versus day 3| 0.006**          | 0.86            |                     |
| Day 1 versus day 2| 0.017*           | 0.95            |                     |
| Day 2 versus day 3| 0.33             | 0.94            |                     |
| 3. Cys-c          |                   |                 |                      |
| Day 0 versus day 1| 0.445            | 0.71            | 0.69                |
| Day 0 versus day 2| 0.045*           | 0.0045**        | 0.45                |
| Day 0 versus day 3| 0.007**          | 0.35            |                     |
| Day 1 versus day 2| 0.11             | 0.66            |                     |
| Day 2 versus day 3| 0.11             | 0.87            |                     |

Day 0 means the day of PBD intake. Day 1, day2 and day3 means one, two and three days after PBD intake. Two way ANOVA $p$-values were shown for each biomarker. Intergroup differences significance was calculated by Dunnett’s multiple comparisons test. * means $p$-value < 0.05, ** means $p$-value < 0.01, while *** means $p$-value < 0.001

### Table 6

| Parameters                        | KIM-1       | NGAL        | Cys-C       |
|----------------------------------|-------------|-------------|-------------|
| Basal levels versus levels 2 days before AKI | 44.23 ± 19.2 | 2.5 ± 3  | 7.31 ± 11.7 |
| Basal levels versus levels 1 days before AKI | 101.9 ± 18.27 | 37.8 ± 2.8 | 27.98 ± 13.1 |
| Basal levels versus levels in the days AKI diagnosis | 116.3 ± 17.31 | 47.02 ± 2.72 | 52.2 ± 15.7 |

Percentage of increase were calculated in each patient with individually. Data is represented as means ±standard deviation of all patients biomarkers increase percentages.
before serum creatinine rise. Interestingly, the increase of the tested markers was specific to renal injury and did not happen in patients without renal drawbacks of PBD.

These changes are in agreement with several previous studies. Gaspari et al. (2010) [34] concluded that the increase of NGAL at day 2 post treatment was a significant predictor of subsequent AKI. The validity of both NGAL and Cys-C to screen Cisplatin-AKI was evaluated by Lin et al. (2013) [35]. Lin and his collages demonstrated that NGAL showed significant increase 12 h after Cisplatin in cases that developed AKI. In the same study, urinary Cys-C was a poor marker for AKI induced by Cisplatin. These different results by Lin et al. may be due to small number of patients (33 patients with only 10 cases showed AKI), different AKI definition (according to RIFLE criteria), and different methods and time points for urinary cystatin measurements, which differ from our study design. In addition Cys-C in their study was expressed as a ratio to urinary creatinine.

Moreover, Tekce et al. (2015) [36] studied 22 patients in Turkey and showed that KIM-1 was significantly increased in 8 cases that developed AKI. Urinary KIM-1 levels were significantly increased 24 h after Cisplatin in cases diagnosed in the 3rd day after treatment, which is in agreement with the current data. Data regarding the second day after Cisplatin was not collected in their paper.

Regarding the changes of the biomarkers in cases of PBD induced AKI during the course of the study, there is discordance between our findings and Lin et al., study who showed early increase in the biomarkers from the basal line within 6 h in cases developed AKI, then the levels declined (but still above the basal levels) to be increased again for another peak within 48 h. This difference in the data may be due to the different hydration protocol and when the samples are collected in relation to the fluids intake as hydration can dilute the urinary biomarkers. In addition they have taken more frequent samples every hour during the whole course of the study.

Interestingly, NGAL showed the highest significant increase in the day of serum creatinine based AKI diagnosis in comparison to their corresponding basal levels. These finding have high clinical significance as they show the benefit of these biomarkers for early screening of PBD induced AKI and showed that serum creatinine increase is a late event in the cascade of events of AKI progress course.

The current study data is important for early screening of cases of AKI. However it has its own limitations as

| Biomarkers | AUC (95% Confidence Interval) | p-value | Cut-off | Sensitivity% | Specificity% |
|------------|-------------------------------|---------|---------|--------------|--------------|
| KIM-1      | 0.9983 (0.9946 to 1.002)      | < 0.0001| < 1.685 | 96.23        | 100.0        |
|            |                               |         | < 1.730 | 96.23        | 97.44        |
|            |                               |         | < 1.750 | 98.11        | 97.44        |
| NGAL       | 1 (1–1)                       | < 0.0001| < 498.0 | 100.0        | 100.0        |
|            |                               |         | < 508.2 | 100.0        | 98.11        |
|            |                               |         | < 511.7 | 100.0        | 96.23        |
| Cys-S      | 1 (1–1)                       | < 0.0001| < 15.43 | 100.0        | 100.0        |
|            |                               |         | < 16.65 | 100.0        | 96.30        |
|            |                               |         | < 16.75 | 100.0        | 94.44        |

Fig. 1 Sensitivity and specificity of the different urinary biomarkers in cases of AKI
other larger multicenter studies are recommended for more robustness of data and will check the data in different groups of patients with different cancers and receiving different PBD and different grades of AKI. Such studies are able to detect sharper cut-off point with higher sensitivity and specificity for the different markers specially KIM-1 which showed better results as an early biomarker.

Conclusion
Acute kidney injury is still a challenging side effect of platinum based agents, in spite of reduced dosage protocols and proper hydration. Urinary KIM-1, Cystatin C and NGAL can predict PBD induced AKI in earlier stages than serum creatinine. KIM-1 is the most sensitive biomarker for early detection of AKI in patients receiving PBD.

Abbreviations
AKI: Acute Kidney Injury; Cys-C: Cystatin-C; KDIGO: Kidney Disease: Improving Global Outcomes; KIM-1: Kidney injury molecule-1; NAG: N-acetyl-β-glucosaminidase; NGAL: Human neutrophil gelatinase-associated lipocalin; PBD: platinum based drugs; B2M: β2-microglobulin

Acknowledgements
We are pleased to acknowledge Mansoura University Hospitals for hosting our research and we are so thankful to our colleagues in radiology department who had evaluated the participant by sonography.

Funding
The research was self-funded by the authors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request to any scientist using the data for non-commercial purposes without any conflict with the participant confidentiality.

Contact Person:
Dr. Ekramy Elmorsy.
Email: ekramy.elmorsy@yahoo.com

Authors’ contributions
SA, EAE, and ZME: Study design and supervision of data collection and results interpretation. AM, AH, AO, NM, AA: Clinical diagnosis, assessment and clinical follow up of the cases enrolled in the study. AMF: Clinical management of the participants with follow up of the hydration protocol. MT, AF and AN: Laboratory work for creatinine and the urinary biomarkers. EA, AAA, EM: Data collection with revision of inclusion and exclusion criteria. EE and AM: Data collection and statistical analysis and scientific writing and submission. All the authors read and approved the final form of the manuscript.

Ethics approval and consent to participate
The current study was approved by Mansoura faculty of Medicine ethical committee. A written informed consent was taken from all participants. Confidentiality and privacy were considered regarding participants’ personal, confidential and laboratory data. All the research data are available.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Mansoura Nephrology and dialysis Unit, Internal Medicine Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt.
2Department of Forensic Medicine and Clinical Toxicology, Mansoura faculty of Medicine, Mansoura, Egypt. 3Internal Medicine Departments, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt. 4Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 5Fellow of Biochemistry, Emergency Hospital, Mansoura University, Mansoura, Egypt. 6Clinical Pathology Department, Mansoura faculty of Medicine, Mansoura, Egypt. 7Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk, Kingdom of Saudi Arabia. 8Department of Population Health and Reproduction, University of California, Davis, California, USA.

Received: 1 March 2018 Accepted: 28 August 2018
Published online: 04 September 2018

References
1. Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care. 2005;11(6):555–65.
2. Waikar SS, Betensky RA, Emerson SC, Bonventre JV. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol. 2012;23(1):13–21.
3. Hsu CY, et al. Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol. 2009;4(9):891–8. PubMed: 19406959.
4. Xue JL, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol. 2006;17(11):35–42. PubMed: 16965881.
5. Berl T. American Society of Nephrology renal research report. J Am Soc Nephrol. 2005; 6. Van Biesen W, Vanholder R, Lameire N. Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol. 2006;1(13):1–9.
7. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G, Matsuoka RA, Betensky RA, Curhan GC, Bonventre JV. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200–8.
8. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1: a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237–44.
9. Sun IO, Shi SH, Cho AY, Yoon HY, Chang MY, Lee KY. Clinical significance of NGAL and KIM-1 for acute kidney injury in patients with scrub typhus. PLoS One. 2017;12(4):e0175890.
10. Zhang PL, Rothblum LI, Han WK, Blasick TM, Potdar S, Bonventre JV. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int. 2008 Mar;73(3):608–14.
11. Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C, et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One. 2014;9(1):e84131. https://doi.org/10.1371/journal.pone.0084131.
12. Uchida K, Gotob A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta. 2002;323(1):121–8.
13. Herget-Rosenthal S, Pietruck F, Volbracht L, Philipp T, Kribben A. Serum cystatin C—a marker of rapidly developing glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin Nephrol. 2005;64(1):41–6.
14. Yuen PS, Jo SK, Holly MK, Hu X, Star RA. Ischemic and nephrotoxic acute renal failure are distinguished by their broad transcriptomic responses. Physiol Genomics. 2006;25(3):375–86.
15. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, Edelstein CL, Devarajan P. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006;6(7):1639–45.
16. Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol. 2010;21(1):189–97.
17. Ali I, A Wani W, Saleem K, Haque A. Platinum compounds: a hope for future cancer chemotherapy. Antibiotiki (Mosc). 2013;52(2):296–300.
18. Kuriakose GC, Kurup MG. Evaluation of renoprotective effect of Aphanizomenon flos-aquae on cisplatin-induced renal dysfunction in rats. Ren Fail. 2008;30(7):717–25.
19. Kang DG, Lee AS, Mun YJ, Woo WH, Kim YC, Sohn EJ, Moon MK, Lee HS. Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats. Biol Pharm Bull. 2004;27(9):366–70.
20. Kawai Y, Satoh T, Hibi D, Ohno Y, Kohda Y, Miura K, Gemba M. The effect of antioxidant on development of fibrosis by cisplatin in rats. J Pharmacol Sci. 2009;111(4):433–9.
21. Barabas K, Milner R, Lurie D, Adlin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2008;6(1):1–8.
22. Labaye J, Sarret D, Ducic C, Héryody M, Didelon P, Nédélec G, Noël LH. Renal toxicity of oxaliplatin. Nephro Dial Transplant. 2005;20(6):1275–6.
23. Ulusakarya A, Misra S, Haydar M, Habert H, Castagne V, Gumus Y, Delmas-Maratea B, Machover D. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol. 2010;27(4):1425–6.
24. Yaghobi Joybari A, Sarbaz S, Azadeh P, Mirashehani SA, Rahbari A, Farazatinasab M, Mokhtari M. Oxaliplatin-induced renal tubular vacuolization. Ann Pharmacother. 2014;48(6):796–800.
25. Isnard-Bagnis C, Launay-Vacher V, Kerie S, Deray G. Anticancer drugs. In: Clinical Nephrotoxins Renal Injury from Drug and Chemicals, edited by De Broe M, Porter G, Bennett W, Deray G, 3rd Ed., New York, Springer Scientific, 511–535 2008.
26. McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med. 1991;90(1):386–91.
27. Agraharkar M, Nerenstone S, Palmisano J, Kaplan AA. Carboplatin-related hematuria and acute renal failure. Am J Kidney Dis. 1998;32(5):e5–1.
28. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera FR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18(1):106.
29. Heinegård D, Tiderström G. Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta. 1973;43(3):305–10.
30. Chaturvedi, Shalini, Takeisha Farmer, and Gordon F. Kapke. “Assay validation for KIM-1: human urinary renal dysfunction biomarker.” Int J Biol Sci 5.2 (2009): 128–134. Print.
31. KDIGO Clinical Practice Guideline for Acute Kidney Injury Kidney International Supplements (2012) 2;1 https://doi.org/10.1038/kisup.2012.1
32. Faig J, Haughton M, Taylor RC, D’Agostino RB Jr, Whelen MJ, Rodriguez KA, Bonomi M, Mures M, Ponsicini M. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol. 2017.
33. Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pac J Cancer Prev. 2015;16(3):1117–22.
34. Gaipari F, Cravedi P, Mandalla M, Perico N, De Leon FR, Stocchi N, Ferrari S, Labianca R, Remuzzi G, Ruggenenti P. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract. 2010;105(2):c154–60.
35. Lin HY, Lee SC, Lin SF, Hisao HH, Liu YC, Yang WC, Hwang DY, Hung CC, Chen HC, Guh JY. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci. 2013;29(6):304–11.
36. Tekce BK, Uyeturk U, Telke H, Uyeturk U, Akbas G, Akkaya A. Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage? Ann Clin Biochem. 2015;52(1):88–94.